SCHEMBL23590329

SCHEMBL23590329

CCOc1cccc(-c2ccc(-c3cc(C(=O)O)c4cc(C(F)(F)F)ccc4n3)cc2)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 5/20 0.58
▸ SMN1; SMN2 Q16637 4/20 0.58
▸ LMNA P02545 3/20 0.58
▸ ALDH1A1 P00352 3/20 0.58
▸ HPGD P15428 2/20 0.58
▸ NPC1 O15118 1/20 0.58
▸ RAB9A P51151 1/20 0.58
▸ HSD17B10 Q99714 4/20 0.55
▸ MEN1 O00255 2/20 0.55
▸ KMT2A Q03164 2/20 0.55
▸ DHODH Q02127 9/20 0.53
▸ TP53 P04637 3/20 0.51
▸ RXRA P19793 1/20 0.51
▸ RXRB P28702 1/20 0.51
▸ CYP1A2 P05177 2/20 0.50
▸ CYP2C19 P33261 1/20 0.50
▸ HIF1A Q16665 1/20 0.50
▸ PDE10A Q9Y233 1/20 0.48
▸ TSHR P16473 1/20 0.48
▸ TDP1 Q9NUW8 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26074176 0.92 PLA2G2A (0.53) KDM4ESMN1; SMN2LMNAALDH1A1HPGD
SCHEMBL23590225 0.91 KDM4E (0.67) KDM4ESMN1; SMN2LMNAALDH1A1HPGD
SCHEMBL23590057 0.91 KDM4E (0.49) KDM4ESMN1; SMN2LMNAALDH1A1HPGD
SCHEMBL23590134 0.89 KDM4E (0.52) KDM4ESMN1; SMN2LMNAALDH1A1HPGD
SCHEMBL23590082 0.87 DHODH (0.69) KDM4ESMN1; SMN2LMNAALDH1A1HPGD
SCHEMBL26075595 0.86 MAP4K4 (0.45) KDM4ESMN1; SMN2LMNAALDH1A1HPGD
SCHEMBL26074029 0.85 KDM4E (0.61) KDM4ESMN1; SMN2LMNAALDH1A1HPGD
SCHEMBL23590238 0.85 KDM4E (0.56) KDM4ESMN1; SMN2LMNAALDH1A1HPGD
SCHEMBL23590291 0.83 KDM4E (0.64) KDM4ESMN1; SMN2LMNAALDH1A1HPGD
SCHEMBL23590257 0.83 DHODH (0.70) KDM4ESMN1; SMN2LMNAALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230303710-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT OHIO STATE INNOVATION FOUNDATION (US) 2023-09-28 — — US disclosed
WO-2023278778-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD47-SIRPΑ THERAPEUTIC AGENT OHIO STATE INNOVATION FOUNDATION (US) 2023-01-05 — — WO disclosed
US-11312686-B2 Methods and compositions for inhibition of dihydroorotate dehydrogenase OHIO STATE INNOVATION FOUNDATION (US) 2022-04-26 — — US disclosed
US-20220064119-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE HENDRIX COLLEGE 2022-03-03 — — US disclosed
US-20210253531-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE OHIO STATE INNOVATION FOUNDATION 2021-08-19 — — US disclosed
WO-2021134045-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT OHIO STATE INNOVATION FOUNDATION (US) 2021-07-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11312686-B2 Methods and compositions for inhibition of dihydroorotate dehydrogenase DHODH, DLD, DPYD KDM4E 474/4885SMN1; SMN2 3650/4885LMNA 4628/4885
US-20230303710-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT DHODH, CD38, DPYD KDM4E 1396/4885SMN1; SMN2 3677/4885LMNA 1972/4885
US-20220064119-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE DHODH, DLD, DPYD KDM4E 523/4885SMN1; SMN2 3708/4885LMNA 4614/4885
US-20210253531-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE DHODH, DLD, DPYD KDM4E 474/4885SMN1; SMN2 3650/4885LMNA 4628/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback